- Lasmiditan
-
-
2024-11-01
- CAS:439239-90-4
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 1000kgs
- Lasmiditan
-
- $15.00
-
2021-07-13
- CAS:439239-90-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Lasmiditan
-
- $15.00
-
2021-07-09
- CAS:439239-90-4
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | LasMiditan Basic information |
| Product Name: | LasMiditan | | Synonyms: | LasMiditan;2,4,6-trifluoro-N-(6-(1-Methylpiperidine-4-carbonyl)pyridin-2-yl)benzaMide;COL-144; LY573144;CS-2381;COL-144; LY-573144;COL144; LY 573144;2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide;LasMiditan (COL-144;Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- | | CAS: | 439239-90-4 | | MF: | C19H18F3N3O2 | | MW: | 377.36 | | EINECS: | | | Product Categories: | API | | Mol File: | 439239-90-4.mol |  |
| | LasMiditan Chemical Properties |
| Melting point | 255℃ | | Boiling point | 433.3±45.0 °C(Predicted) | | density | 1.351 | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | Chloroform (Slightly), DMSO (Slightly) | | pka | 9.91±0.70(Predicted) | | form | Solid | | color | White to Off-White |
| | LasMiditan Usage And Synthesis |
| Description | Lasmiditan (Item No. 28369) is an analytical reference standard categorized as an agonist of the serotonin (5-HT) receptor subtype 5-HT1F. Formulations containing lasmiditan have been used in the treatment of migraine headache. Lasmiditan has low abuse potential. Lasmiditan is regulated as a Schedule V compound in the United States. This product is intended for research and forensic applications. | | Uses | Lasmiditan is used in diagnosing, treating and/or preventing periodontal disease and/or tooth loss. | | Synthesis | synthesis route of LasMiditan
 | | References | [1] DAVID L NELSON. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.[J]. ACS Applied Materials & Interfaces, 2010: 1159-1169. DOI: 10.1177/0333102410370873 [2] DARREN WILBRAHAM MBBS, PHD. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study[J]. The Journal of Clinical Pharmacology, 2019, 60 4: 495-504. DOI: 10.1002/jcph.1543 |
| | LasMiditan Preparation Products And Raw materials |
|